Toxins 2011, 3(8), 1004-1019; doi:10.3390/toxins3081004

Monoclonal Antibody Therapies against Anthrax

1,* email, 2email and 1email
Received: 10 June 2011; in revised form: 6 August 2011 / Accepted: 10 August 2011 / Published: 15 August 2011
(This article belongs to the Special Issue Anthrax Toxin)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.
Keywords: Bacillus anthracis; anti-PA mAbs; anti-LF mAbs; anti-EF mAbs; anti-capsule mAbs; post-exposure treatment of anthrax; a cocktail of mAbs
PDF Full-text Download PDF Full-Text [197 KB, uploaded 15 August 2011 08:29 CEST]

Export to BibTeX |

MDPI and ACS Style

Chen, Z.; Moayeri, M.; Purcell, R. Monoclonal Antibody Therapies against Anthrax. Toxins 2011, 3, 1004-1019.

AMA Style

Chen Z, Moayeri M, Purcell R. Monoclonal Antibody Therapies against Anthrax. Toxins. 2011; 3(8):1004-1019.

Chicago/Turabian Style

Chen, Zhaochun; Moayeri, Mahtab; Purcell, Robert. 2011. "Monoclonal Antibody Therapies against Anthrax." Toxins 3, no. 8: 1004-1019.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert